EVAX (Evaxion AS) YoY EBITDA Growth: 48.89% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVAX Evaxion AS EVAX
48 GF Score
Price $3.03
GF Value $3.34
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Evaxion AS YoY EBITDA Growth?

Evaxion AS EVAX -4.44% 48 YoY EBITDA Growth is 48.89% as of Jun. 2026. GuruFocus rates EVAX with a GF Score™ of 48/100 and a GF Value™ of $3.34 (Fairly Valued). The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Evaxion AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 48.89%.

Evaxion AS's EBITDA per Share for the three months ended in Jun. 2026 was $-0.51.

Evaxion AS YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Evaxion AS's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS YoY EBITDA Growth Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -22.32 23.12 18.01 76.69 87.81

Evaxion AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.43 160.27 78.90 -69.08 48.89
EVAX
48GF Score
Evaxion AS EVAX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Evaxion AS's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.112--9.12)/ | -9.12 |
=87.81 %

Evaxion AS's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.506--0.99)/ | -0.99 |
=48.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 48.89% mean?
Evaxion AS (EVAX) has a YoY EBITDA Growth of 48.89% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Evaxion AS and its competitors.
Is Evaxion AS's YoY EBITDA Growth too high?
Evaxion AS's current YoY EBITDA Growth is 48.89%. Overall, Evaxion AS has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's YoY EBITDA Growth compare to CRVO and ALGS?
Evaxion AS's YoY EBITDA Growth of 48.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Evaxion AS and its competitors. Evaxion AS's current YoY EBITDA Growth is 48.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.34, compared to a current price of $3.03 — trading 9.3% below its estimated fair value. The current YoY EBITDA Growth is 48.89%. Evaxion AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Evaxion AS (EVAX), the current YoY EBITDA Growth is 48.89% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evaxion AS (EVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued. The current stock price of $3.03 is trading 9.3% below its estimated GF Value™ of $3.34. GuruFocus considers Evaxion AS to be Fairly Valued.

Key valuation signals for EVAX:

  • YoY EBITDA Growth: 48.89%
  • GF Value™: $3.34 vs. price of $3.03 (9.3% below fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
48GF Score

Get the complete analysis for EVAX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.03
Price
$3.34
GF Value